Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions

Area of Science:

• Vascular Surgery
• Cardiology
• Pharmacology

Background:

• Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) face high risks of cardiovascular and limb ischemic events.
• Antithrombotic therapy is crucial for preventing thrombotic complications but must balance the increased risk of bleeding.
• Dual pathway inhibition (DPI) presents a strategy to mitigate these risks.

Purpose of the Study:

• To evaluate the efficacy and safety of dual pathway inhibition (DPI) therapy in patients with PAD post-LER.
• To assess the reduction in major adverse cardiovascular and limb-related events.
• To determine the impact on major bleeding events.

Main Methods:

• Aspirin combined with low-dose rivaroxaban (dual pathway inhibition) was administered to PAD patients following LER.
• Outcomes including major adverse cardiovascular and limb-related events were monitored.
• Major bleeding events were assessed to evaluate safety.

Main Results:

• DPI therapy demonstrated a reduction in major adverse cardiovascular and limb-related events.
• The incidence of major bleeding events showed no significant difference compared to standard therapies.
• The findings support the effectiveness of DPI in this high-risk patient population.

Conclusions:

• Dual pathway inhibition (aspirin plus low-dose rivaroxaban) is effective in reducing adverse events in PAD patients after LER.
• This strategy offers a favorable balance between preventing ischemic events and managing bleeding risk.
• Broad implementation of DPI therapy in routine practice for PAD patients post-LER is warranted.